Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Unveils Co-Beneldopa Capsules
Teva UK (Teva) has launched generic co-Beneldopa capsules in a variety of strengths. The company said that they are the first generic to reach the market. Co-Beneldopa is
Teva UK (Teva) has launched generic co-Beneldopa capsules in a variety of strengths. The company said that they are the first generic to reach the market. Co-Beneldopa is
National Institutes of Health (NIH) has presented data from the clinical trial on Revlimid. Initial results from a large, randomised clinical trial for patients with multiple myeloma, showed
Mesa Laboratories has acquired the bottle cap torque testing business of Vibrac, a new Hampshire based company. Under this transaction, Vibrac is expected to sell the assets associated
Global Med Technologies (Global Med) has reported that its Inlog, subsidiary has licensed its EdgeLab Laboratory Information Management Software to the centuries-old Centre Hospitalier de Verdun in Verdun,
Galapagos has expanded its arthritis alliance with GlaxoSmithKline (GSK) to include additional drug discovery programs based on novel drug target, GT622. As per the terms of the extension,
Avedro has presented encouraging early clinical results for treating keratoconus, during the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th. Keraflex
Ipsen has announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for Taspoglutide,
Cell Therapeutics (CTI) has reported that on February 10, 2010, the FDA’s Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for Pixantrone, for the
Forest Laboratories and Almirall have entered into an agreement to develop, market and distribute LAS100977 in the US. LAS100977 is an inhaled, once-daily administered long-acting beta2 agonist (LABA),
Japan-based Eisai has reported completion of construction of a new manufacturing and process research center in India. Eisai Knowledge Centre is situated in the special economic zone (SEZ)